Valuation: Zeo ScientifiX, Inc.

Market Cap 13.87M 12.19M 11.33M 10.42M 19.53M 1.34B 19.91M 135M 52.76M 654M 52.07M 50.95M 2.27B P/E 2024
-2.29x
P/E 2025 -2.17x
Enterprise Value 14M 12.31M 11.44M 10.52M 19.72M 1.35B 20.1M 136M 53.27M 660M 52.57M 51.44M 2.29B EV / Sales 2024
2.43x
EV / Sales 2025 2.45x
Free-Float
64.39%
Yield 2024 *
-
Yield 2025 -
06-15 Zeo ScientifiX, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026 CI
06-09 Zeo Scientifix, Inc. Announces Management Changes CI
04-09 Zeo Scientifix Inc - enters MoU with Regen Therapy for exclusive scientific and biologics collaboration - SEC filing RE
04-09 Regen Therapy Partners with Stealth Health to Bring Specialized Telemedicine Services and Longevity Programs to 3,000 Clinics-Powered by an Exclusive Scientific and Biologics Strategic Collaboration with ZEO Scientifix CI
03-27 Zeo Scientifix, Inc. Announces Termination of Dr. John D. Kisiday as Chief Science Officer Effective March 23, 2026 CI
03-17 Zeo ScientifiX, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2026 CI
01-29 Zeo ScientifiX, Inc. Reports Earnings Results for the Full Year Ended October 31, 2025 CI
01-28 Zeo ScientifiX, Inc. Auditor Raises 'Going Concern' Doubt CI
01-28 Zeo Scientifix, Inc. Appoints John D. Kisiday as Chief Science Officer, Effective January 23, 2026 CI
01-07 Cytora Therapeutics, Made Scientific, and Zeo Scientifix Announce Partnership to Manufacture and Commercialize Cytora's Allogeneic Stem Cell Therapy in the United States CI
01-07 Cytora Therapeutics partners with Made Scientific, and Zeo Scientifix to manufacture allogeneic stem cell therapy RE
01-05 Zeo ScientifiX, Inc. Appoints Ian T. Bothwell as Full-Time Chief Executive Officer, Effective December 24, 2025 CI
12-03 Zeo Scientifix, Inc. Terminates Ron Borsheim as Chief Sales Officer Aesthetics, Effective November 30, 2025 CI
1 day+4.73%
1 week-8.76%
Current month-0.56%
1 month+6.63%
3 months-4.17%
6 months-34.20%
Current year-34.69%
1 week 1.58
Extreme 1.58
1.82
1 month 1.58
Extreme 1.58
2.18
Current year 1.32
Extreme 1.32
2.98
1 year 1.2
Extreme 1.2
2.99
3 years 0.8
Extreme 0.8
4.78
5 years 0.8
Extreme 0.8
24.5
10 years 0.7
Extreme 0.7
125.98
Manager TitleAgeSince
Chief Executive Officer 65 31/05/2024
Chief Tech/Sci/R&D Officer - 31/12/2019
Compliance Officer - 31/03/2025
Director TitleAgeSince
Director/Board Member 65 10/09/2019
Director/Board Member 78 22/09/2022
Director/Board Member 64 18/08/2022
Date Insider Type Main position Quantity % Market Cap.
10/06/26
Greyt Ventures LLC
FreeCompany 1,250,000 16.0721%
10/06/26 Free

Chief Technology Officer

1,250,000 16.0721%
10/06/26 Free

Chairman

80,000 1.0286%
Change 5-day change 1-year change 3-year change Capi.($)
+4.73%-8.76%-13.24%-57.86% 13.87M
+1.28%+3.53%+16.21%+99.03% 95.31B
+2.47%+0.46%+43.84%+142.49% 51.65B
-0.69%-2.05%+3.61%+250.00% 23.26B
-0.96%-1.66%-13.50%-18.68% 8.29B
-1.33%-3.31%-30.90%-30.77% 7.98B
-0.35%-2.98%-11.27%-29.46% 6.76B
-0.84%+2.81%+25.47%+27.58% 6.29B
-2.63%-0.11%-1.97%+20.46% 5.48B
0.00%-1.94%-6.47%-7.22% 3.73B
Average +0.17%-0.57%+1.18%+39.56% 20.88B
Weighted average by Cap. +0.92%+0.64%+17.17%+106.68%

Financials

2024 2025
Net sales 4.62M 4.06M 3.77M 3.47M 6.51M 446M 6.63M 45M 17.57M 218M 17.34M 16.97M 757M 5.2M 4.57M 4.25M 3.9M 7.32M 502M 7.46M 50.63M 19.77M 245M 19.51M 19.1M 852M
Net income -4.7M -4.14M -3.84M -3.53M -6.63M -454M -6.75M -45.82M -17.9M -222M -17.66M -17.28M -771M -5.52M -4.85M -4.51M -4.15M -7.77M -533M -7.92M -53.77M -21M -260M -20.72M -20.28M -904M
Net Debt 36K 31.64K 29.4K 27.04K 50.69K 3.48M 51.67K 351K 137K 1.7M 135K 132K 5.9M 132K 116K 108K 99.14K 186K 12.75M 189K 1.29M 502K 6.22M 495K 485K 21.62M
Logo Zeo ScientifiX, Inc.
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company. The Company is primarily focused on developing innovative biological therapeutics for regenerative medicine and the treatment of degenerative diseases. Its proprietary products, including Zofin, which are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles, and Patient Pure X (PPX), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient’s own peripheral blood (RAAM Products). Its RAAM Products and related services are principally used in the health care industry administered through doctors and clinics. It has developed and begun to distribute additional products that incorporate its proprietary ingredients for products to be used in topical aesthetic applications and is actively exploring further development of additional products to be used in other topical aesthetic applications.
Employees
20
Date Price Change Volume
22/07/26 US$1.770 +4.73% 430
21/07/26 US$1.690 -6.11% 8,933
20/07/26 US$1.800 -1.10% 975
17/07/26 US$1.820 +1.68% 2,570
16/07/26 US$1.790 -7.73% 3,077
  1. Stock Market
  2. Stocks
  3. ZEOX Stock